{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:16:37Z","timestamp":1792030597413,"version":"4.4.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017577","name":"CTI Biopharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017577","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17lk0103012"],"award-info":[{"award-number":["JP17lk0103012"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ymgme.2023.107709","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T03:17:14Z","timestamp":1697599034000},"page":"107709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II: Final report of 5-year results from a Japanese open-label phase 1\/2 study"],"prefix":"10.1016","volume":"140","author":[{"given":"Joo-Hyun","family":"Seo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motomichi","family":"Kosuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Hamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruo","family":"Shintaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torayuki","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2023.107709_bb0005","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1750-1172-6-72","article-title":"Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease","volume":"6","author":"Scarpa","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2023.107709_bb0010","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/21678707.2017.1296761","article-title":"Presentation and treatments for mucopolysaccharidosis type II (MPS II; hunter syndrome), expert","volume":"5","author":"Stapleton","year":"2017","journal-title":"Opin. Orphan. Drugs."},{"key":"10.1016\/j.ymgme.2023.107709_bb0015","article-title":"Natural history of cognitive development in neuronopathic mucopolysaccharidosis type II (hunter syndrome): contribution of genotype to cognitive developmental course","volume":"24","author":"Seo","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2023.107709_bb0020","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ymgme.2021.03.002","article-title":"The natural history of neurocognition in MPS disorders: a review","volume":"133","author":"Shapiro","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.107709_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2017.08.009","article-title":"Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations \u2014 neurological signs and symptoms","volume":"122S","author":"Shapiro","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.107709_bb0030","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.2147\/DDDT.S139601","article-title":"Development of idursulfase therapy for mucopolysaccharidosis type II (hunter syndrome): the past, the present and the future","volume":"11","author":"Whiteman","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ymgme.2023.107709_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030341","article-title":"CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder","volume":"7","author":"Calias","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2023.107709_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164765","article-title":"Biodistribution of idursulfase formulated for intrathecal use (idursulfase-IT) in cynomolgus monkeys after intrathecal lumbar administration","volume":"11","author":"Chung","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2023.107709_bb0045","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s10545-018-0221-0","article-title":"The efficacy of intracerebroventricular idursulfase-beta enzyme replacement therapy in mucopolysaccharidosis II murine model: heparan sulfate in cerebrospinal fluid as a clinical biomarker of neuropathology","volume":"41","author":"Sohn","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2023.107709_bb0050","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ymgme.2022.07.017","article-title":"Intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II: results from a phase 2\/3 randomized study","volume":"137","author":"Muenzer","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2023.107709_bb0055","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ymgme.2022.07.016","article-title":"Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II","volume":"137","author":"Muenzer","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.107709_bb0060","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/gim.2015.36","article-title":"A phase I\/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II","volume":"18","author":"Muenzer","year":"2016","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2023.107709_bb0065","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.gim.2022.04.002","article-title":"Long-term open-label phase I\/II extension study of intrathecal idursulfase-IT in the treatment of neuronopathic mucopolysaccharidosis II","volume":"24","author":"Muenzer","year":"2022","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2023.107709_bb0070","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymthe.2018.12.005","article-title":"Iduronate-2-sulfatase with anti-human transferrin receptor antibody for neuropathic mucopolysaccharidosis II: a phase 1\/2 trial","volume":"27","author":"Okuyama","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2023.107709_bb0075","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ymthe.2020.09.039","article-title":"A phase 2\/3 trial of pabinafusp alfa, IDS fused with anti-human transferrin receptor antibody, targeting neurodegeneration in MPS-II","volume":"29","author":"Okuyama","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2023.107709_bb0080","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00109-017-1562-0","article-title":"Adeno-associated viral gene therapy for mucopolysaccharidoses exhibiting neurodegeneration","volume":"95","author":"Lau","year":"2017","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/j.ymgme.2023.107709_bb0085","series-title":"Interview Form - Hunterase\u00ae ICV Injection 15 mg [Japanese]","author":"Clinigen","year":"2022"},{"key":"10.1016\/j.ymgme.2023.107709_bb0090","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/jhg.2016.133","article-title":"Comparative study of idursulfase beta and idursulfase in vitro and in vivo","volume":"62","author":"Kim","year":"2017","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2023.107709_bb0095","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ymgme.2014.08.009","article-title":"Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with hunter syndrome","volume":"114","author":"Sohn","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.107709_bb0100","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1750-1172-8-42","article-title":"Phase I\/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (hunter syndrome)","volume":"8","author":"Sohn","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2023.107709_bb0105","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.omtm.2021.02.018","article-title":"Impact of intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II","volume":"21","author":"Seo","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymgme.2023.107709_bb0110","series-title":"Package Insert - Hunterase\u00ae ICV Injection 15 Mg [Japanese]","author":"Clinigen","year":"2022"},{"key":"10.1016\/j.ymgme.2023.107709_bb0115","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.cca.2012.01.012","article-title":"An improved method for glycosaminoglycan analysis by LC\u2013MS\/MS of urine samples collected on filter paper","volume":"413","author":"Auray-Blais","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2023.107709_bb0120","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1373\/clinchem.2010.161141","article-title":"Analysis of glycosaminoglycans in cerebrospinal fluid from patients with mucopolysaccharidoses by isotope-dilution ultra-performance liquid chromatography-tandem mass spectrometry","volume":"57","author":"Zhang","year":"2011","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymgme.2023.107709_bb0125","series-title":"Kyoto Kokusai Shakaifukushi Center","article-title":"The guide of Kyoto scale of psychological development","author":"Ikuzawa","year":"2001"},{"key":"10.1016\/j.ymgme.2023.107709_bb0130","first-page":"28","article-title":"Case report of treatment experience with idursulfase beta (Hunterase) in an adolescent patient with MPS II","volume":"12","author":"Ngu","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2023.107709_bb0135","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","article-title":"Mucopolysaccharidosis type II (hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy","volume":"167","author":"Wraith","year":"2008","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2023.107709_bb0140","first-page":"103","article-title":"Levels of glycosaminoglycans in the cerebrospinal fluid of healthy young adults, surrogate-normal children, and hunter syndrome patients with and without cognitive impairment","volume":"5","author":"Hendriksz","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2023.107709_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2326409815595821","article-title":"A cerebrospinal fluid collection study in pediatric and adult patients with hunter syndrome","volume":"3","author":"Hendriksz","year":"2015","journal-title":"J. Inborn Errors Metab. Screen."},{"key":"10.1016\/j.ymgme.2023.107709_bb0150","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1073\/pnas.252784899","article-title":"Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB","volume":"100","author":"Ohmi","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2023.107709_bb0155","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/jnr.21134","article-title":"Cytokines, neurotrophins, and oxidative stress in brain disease from mucopolysaccharidosis IIIB","volume":"85","author":"Villani","year":"2007","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.ymgme.2023.107709_bb0160","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/BF00992503","article-title":"GM2 ganglioside and pyramidal neuron dendritogenesis","volume":"20","author":"Walkley","year":"1995","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ymgme.2023.107709_bb0165","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1182\/blood.V91.7.2601","article-title":"Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The storage disease collaborative study group","volume":"91","author":"Peters","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2023.107709_bb0170","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13023-018-0816-4","article-title":"Status of newborn screening and follow up investigations for mucopolysaccharidoses I and II in Taiwan","volume":"13","author":"Chuang","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2023.107709_bb0175","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13052-018-0552-3","article-title":"Newborn screening in mucopolysaccharidoses","volume":"44","author":"Donati","year":"2018","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.ymgme.2023.107709_bb0180","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jpeds.2018.09.063","article-title":"Taiwan national newborn screening program by tandem mass spectrometry for mucopolysaccharidoses types I, II, and VI","volume":"205","author":"Chan","year":"2019","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2023.107709_bb0185","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jpeds.2019.09.036","article-title":"Newborn screening for mucopolysaccharidoses: results of a pilot study with 100000 dried blood spots","volume":"216","author":"Scott","year":"2020","journal-title":"J. Pediatr."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719223003396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719223003396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T12:15:07Z","timestamp":1735215307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719223003396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1096719223003396"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2023.107709","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II: Final report of 5-year results from a Japanese open-label phase 1\/2 study","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2023.107709","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107709"}}